If you have been reading about pentadecapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-14. Numbers and descriptions here follow the published literature rather than marketing material.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
This is achieved, in part, by reactivating foetal haemoglobin production in place of the haemoglobin S that causes sickling. Hydroxyurea lowers the expression of adhesion molecules on endothelial and red blood cells, which lowers the chance of small vessel blockages. Additionally, it encourages the release of nitric oxide, which enhances blood flow and inhibits clot formation. Hydroxyurea had previously been used as a chemotherapy agent. Some concern exists that long-term use may be harmful. A Cochrane review in 2022 found a weak evidence base for its use in sickle cell disease. Despite expanding progress in gene therapy for SCD treatment, hydroxyurea remains a cornerstone first line therapy. However, it is severely underutilized despite the reduction of vaso-occlusive crises by approximately 44% and reduced hospitalizations. In 2019, the United States granted accelerated approval to the medication Voxelotor to treat sickle cell disease. It was approved by the European Medicines Agency (EMA) in 2021. In trials, it had been shown to have disease-modifying potential by increasing haemoglobin levels and decreasing hemolysis indicators However, following an increased risk of vaso-occlusive seizures and death observed in registries and clinical trials, the manufacturer, Pfizer, withdrew it from the market worldwide.
Subsequent studies in 1995 confirmed that the db gene encodes the leptin receptor, and that it is expressed in the hypothalamus, a region of the brain known to regulate the sensation of hunger and body weight.
== Activities == The activity in Chromatography spans HPLC, LC/MS, FPLC, MPLC - GC, GC/MS, GPC, GFC - RMN - AA, IR, ICP, UV – SPE. Interchim notably introduced new generation silica chromatography media (UptiSphere that has become a standard worldwide, Strategy, Atoll). The activity in Fine Chemistry deals with compounds libraries (Chirals, Fluorines, Building blocks for Combi-Chemistry) and flash chromatography. Interchim developed a unique flash chromatography system (PuriFlashEvo430 - integrated functions). The activity in BioSciences focuses on Immunodetection, Biochemistry, Electrophoresis and Cell Assays. Interchim manufactures protein assays (BC Assay, Coo Assay), superior fluorescent dyes known as FluoProbes, Cell Assays reagents and kits (i.e. FluoProbes indicators, high sensitive viability assay UptiBlue) and an innovate transfection agent UptiFectin.
=== In Mount Lebanon === The "Druze-Christian alliance" during the Emirate of Mount Lebanon, from the mid-16th to the early-19th century, and the "Maronite-Druze dualism" in Mount Lebanon Mutasarrifate from the 19th to the 20th centuries, laid the foundation for what is now Lebanon. This is celebrated as establishing a kind of Druze-Maronite condominium, often depicted as the precursor of Lebanese statehood and Lebanese national identity. While Lebanese nationalism appeals to the Lebanese Maronite and Druze communities, it is generally unpopular among Lebanese Muslims, who often support Pan-Arabism and Pan-Islamism, as well as among Greek Orthodox Christians. Druze author Yusuf Khatat Abu Shaqra, in his book Movements in Lebanon, stated: "In the past, there was no discord or estrangement between the Druze and Christians in Lebanon, as there has been since the year 1800. Instead, the two communities had affection for one another, were friendly, and, in other words, operated as one group, working together in harmony".
Sources: en.wikipedia.org
of the electron was first measured by J. J. Thomson. By doing this he showed that the electron, which was postulated before in order to explain electricity, was in fact a particle with a mass and a charge and that its mass-to-charge ratio was much smaller than the one for the hydrogen ion H+. In 1913 he measured the mass-to-charge ratio of ions with an instrument he called a parabola spectrograph. Although this data was not represented as a modern mass spectrum, it was similar in meaning. Eventually there was a change to the notation as m/e giving way to the current standard of m/z. Early in mass spectrometry research the resolution of mass spectrometers did not allow for accurate mass determination. Francis William Aston won the Nobel prize in Chemistry in 1922. "For his discovery, by means of his mass spectrograph, of isotopes, in a large number of non-radioactive elements, and for his enunciation of the Whole Number Rule." In which he stated that all atoms (including isotopes) follow a whole-number rule This implied that the masses of atoms were not on a scale but could be expressed as integers (in fact multiple charged ions were rare, so for the most part the ratio was whole as well). There have been several suggestions (e.g. the unit thomson) to change the official mass spectrometry nomenclature
=== Pharmacokinetics === RO5203648 showed favorable pharmacokinetics orally and intravenously in mice, rats, and monkeys. However, it was found to be very rapidly metabolized in human hepatocytes in vitro.
The DSM-5 characterizes diagnosis under several categories—mild, moderate, severe, and extreme—each determined by the number of binges the patient exhibits per week. Mild: 1–3 episodes per week, Moderate: 4–7 episodes per week, Severe: 8–13 episodes per week, Extreme: 14 or more episodes per week Further, the remission states are classified under the following. Partial Remission: Following a previous diagnosis, the average frequency of binge eating episodes decreases to less than one episode per week for a sustained period. Full Remission: Following a previous diagnosis, none of the criteria have been met for a sustained period.
The organization of solvent systems into "families" has greatly facilitated the choice of solvent systems as well. A solvent system can be tested with a one-flask partitioning experiment. The measured partition coefficient from the partitioning experiment will indicate the elution behavior of the compound. Typically, it is desirable to choose a solvent system where the target compound(s) have a partition coefficient between 0.25 and 8. Historically, it was thought that no commercial countercurrent chromatograph could cope with the high viscosities of ionic liquids. However, modern instruments that can accommodate 30 to 70+ % ionic liquids (and potentially 100% ionic liquid, if both phases are suitably customized ionic liquids) have become available. Ionic liquids can be customized for polar / non-polar organic, achiral and chiral compounds, bio-molecule, and inorganic separations, as ionic liquids can be customized to have extraordinary solvency and specificity. After the biphasic solvent system has been chosen a batch of is formulated and equilibrated in a separatory funnel. This step is called pre-equilibration of the solvent system. The two phases are separated. Then the column is filled with stationary with a pump. Next, the column is set an equilibration conditions, such as the desired rotation speed, and the mobile phase is pumped through the column. The mobile phase displaces the a portion of the stationary phase until column equilibration is achieved and the mobile phase elutes from the column.
== Function == Within blood, thrombins cleave fibrinogens to fibrins during coagulation and a fibrin-based blood clot forms. Factor XIII is a transglutaminase that circulates in human blood as a heterotetramer of two A and two B subunits. Factor XIII binds to the clot via their B units. In the presence of fibrins, thrombin efficiently cleaves the R37–G38 peptide bond of each A unit within a XIII tetramer. A units release their N-terminal activation peptides. Both of the non-covalently bound B units are now able to dissociate from the tetramer with the help of calcium ions (Ca2+) in the blood; these ions also activate the remaining dimer of two A units via a conformational change. Factor XIIIa (dimer of two active A units) crosslinks fibrins within the clot by forming isopeptide bonds between various glutamines and lysines of the fibrins. These bonds make the clot physically more durable and protect it from premature enzymatic degradation (fibrinolysis). In humans, plasmin, antithrombin and TFPI are the most relevant proteolytic inhibitors of the active factor XIIIa. α2-macroglobulin is a significant non-proteolytic inhibitor.
Sources: en.wikipedia.org
The findings of the study were overall regarded as not supporting the hypothesis that (R)-MDMA would produce equivalent therapeutic effects as (S)-MDMA or MDMA whilst reducing safety concerns. However, more clinical studies were called for to assess the revised estimated equivalent doses of MDMA, (R)-MDMA, and (S)-MDMA.
== Elements == An expression vector has features that any vector may have, such as an origin of replication, a selectable marker, and a suitable site for the insertion of a gene like the multiple cloning site. The cloned gene may be transferred from a specialized cloning vector to an expression vector, although it is possible to clone directly into an expression vector. The cloning process is normally performed in Escherichia coli. Vectors used for protein production in organisms other than E.coli may have, in addition to a suitable origin of replication for its propagation in E. coli, elements that allow them to be maintained in another organism, and these vectors are called shuttle vectors.
Stercobilin is a tetrapyrrolic bile pigment and is one end-product of heme catabolism. It is the chemical responsible for the brown color of human feces and was originally isolated from feces in 1932. Stercobilin (and related urobilin) can be used as a marker for biochemical identification of fecal pollution levels in rivers.
A scenario is a set of related concepts pertinent to the origin of life (abiogenesis), such as the iron-sulfur world. Many alternative abiogenesis scenarios have been proposed by scientists in a variety of fields from the 1950s onwards in an attempt to explain how the complex mechanisms of life could have come into existence. These include hypothesized ancient environments that might have been favourable for the origin of life, and possible biochemical mechanisms.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.